AXS-02: Phase III started

Axsome began the double-blind, placebo-controlled, international Phase III CREATE-1 to evaluate once-weekly oral AXS-02 for 6 weeks in 190 patients with pain associated with CRPS. AXS-02 has Fast Trac...